Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinoma

Key Points

• To evaluate the effectiveness of a new metabolic signature, LMetSig, in predicting recurrence in resected lung adenocarcinoma.
• Analyzed metabolic signature alongside conventional clinical parameters.
• Stratified lung adenocarcinoma patients based on recurrence risk.
• Compared outcomes of high-risk and low-risk groups.
• LMetSig significantly improved patient stratification.
• High-risk patients were effectively distinguished from those with favorable prognosis.
• Personalized treatment strategies can be informed by these findings.

Abstract